2552 — Hua Medicine Share Price
0.000.00%
Last trade - 00:00- HK$1.51bn
- HK$120.71m
- CNY76.61m
- 27
- 19
- 38
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.34 | ||
| Price to Tang. Book | 19.98 | ||
| Price to Free Cashflow | 1.65 | ||
| Price to Sales | 18.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.8% | ||
| Return on Equity | -110.96% | ||
| Operating Margin | -265.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | 17.6 | 76.61 | 539 | 808 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Directors
- Robert Nelsen NEC (58)
- Li Chen CEO (56)
- Chien Cheng Lin CFO (51)
- Yunlong Du SVP (54)
- Yong-Guo Li SVP (52)
- Yi Zhang SVP (44)
- Fuxing Tang CTO
- YiLei Fu VPR (48)
- Jin She VPR (45)
- Wenjie Xu VPR (47)
- Wing Yan Yuen SEC
- Lian Yong Chen NED (58)
- William Keller NID (73)
- Teh-Ming Kwauk NID (68)
- Junling Liu NID (56)
- Yiu Wa Tsui NID (72)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 10th, 2009
- Public Since
- September 14th, 2018
- No. of Employees
- 177
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 980,522,057
- Address
- Hua Medicine, 275 Ai Di Sheng Road, SHANGHAI, 201203
- Web
- https://www.huamedicine.com
- Phone
- +86 2158869997
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 2552
Hua Medicine Annual Shareholders Meeting
Half Year 2024 Hua Medicine Earnings Release
Similar to 2552
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Hua Medicine share price?
As of Today at 21:12 UTC, shares in Hua Medicine are trading at HK$1.59. This share price information is delayed by 15 minutes.
How has the Hua Medicine share price performed this year?
Shares in Hua Medicine last closed at HK$1.59 and the price had moved by +6.71% over the past 365 days. In terms of relative price strength the Hua Medicine share price has outperformed the FTSE Developed Asia Pacific Index by +2.11% over the past year.
What are the analyst and broker recommendations for Hua Medicine?
The overall consensus recommendation for Hua Medicine is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Hua Medicine dividend yield?
Hua Medicine does not currently pay a dividend.
Does Hua Medicine pay a dividend?
Hua Medicine does not currently pay a dividend.
When does Hua Medicine next pay dividends?
Hua Medicine does not currently pay a dividend.
How do I buy Hua Medicine shares?
To buy shares in Hua Medicine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hua Medicine?
As of the previous close price of HK$1.59, shares in Hua Medicine had a market capitalisation of HK$1.56bn.
Where are Hua Medicine shares listed?
Here are the trading details for Hua Medicine:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2552
What kind of share is Hua Medicine?
Based on an overall assessment of its quality, value and momentum Hua Medicine is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hua Medicine share price forecast for 2024?
The analyst consensus target price for shares in Hua Medicine is HK$3.52. That is 121.09% above the last closing price of HK$1.59.
Analysts covering Hua Medicine currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.44 for the next financial year.
What is the trend in the Hua Medicine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hua Medicine. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -16.25%.
As of the last closing price of HK$1.59, shares in Hua Medicine were trading -6.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hua Medicine PE Ratio?
The Hua Medicine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hua Medicine?
Hua Medicine's management team is headed by:
- Robert Nelsen - NEC
- Li Chen - CEO
- Chien Cheng Lin - CFO
- Yunlong Du - SVP
- Yong-Guo Li - SVP
- Yi Zhang - SVP
- Fuxing Tang - CTO
- YiLei Fu - VPR
- Jin She - VPR
- Wenjie Xu - VPR
- Wing Yan Yuen - SEC
- Lian Yong Chen - NED
- William Keller - NID
- Teh-Ming Kwauk - NID
- Junling Liu - NID
- Yiu Wa Tsui - NID